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Cholangiocarcinoma is a primary liver cancer associated with high mortality (<10% 5-
year survival rate) and limited treatment options. Moreover, the incidence of intrahepatic 
cholangiocarcinoma has risen by 165% since 1975; an escalation not from increased 
early detection. Thus, there is need for a reproducible tumor model and drug delivery 
approach. Nanoparticles offer an effective delivery system of regulatory nucleic acids. 
miR-210 antagonism enhanced tumor cell death upon gemcitabine and cisplatin 
treatment, and polymeric nanoparticles containing a CXCR4 inhibitor (PCX) targeted 
delivery to the liver tumor. To test anti-miR-210 in liver tumors, we injected human 
tumor cells directly into the lobe of a liver that had been cholestatically damaged via 
selective bile duct ligation. We used NOD-SCID mice and injected Mz-ChA-1 cells into 
the left lateral lobe. All mice to undergo this procedure developed tumors within their 
liver, as well as extensive peritoneal metastases. This model was used to test survival 
of mice in four treatment groups: Vehicle, gemcitabine/cisplatin, PCX with anti-miR-210 
plus gem/cis, and PXC with anti-miR-210 without gem/cis. Results showed significantly 
increased survival of all treated groups in comparison to the vehicle group, however 
there was no significantly increased survival in anti-miR-210 treatment groups when 
compared to gem/cis alone. It should be noted that the survival benefit of all treatments 
was driven by responses in females, whereas males had no significant survival 
advantage for treated groups over control. Females also had significant survival in the 
specific treatment group PCX with anti-miR-210. This could suggest a possible role of 
sex as a biological variable for treatment responsiveness and warrants more 
exploration.  
